Skip to main
NBP

NovaBridge Biosciences (NBP) Stock Forecast & Price Target

NovaBridge Biosciences (NBP) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NovaBridge Biosciences is a promising biotechnology company with a focus on developing innovative immuno-oncology treatments. Its lead asset, givastomig, has received positive feedback from the FDA and is well-positioned to integrate into traditional chemotherapy and immunotherapy regimens for the treatment of gastric cancer. Additionally, its second asset, VIS-101, has shown promising data with extended intraocular residence time and has the potential to become a best-in-class anti-VEGF therapy. As the company continues to develop and execute globally relevant clinical programs, its potential addressable market and value could significantly increase.

Bears say

NovaBridge Biosciences is in a strong position with its innovative immuno-oncology pipeline consisting of three clinical stage programs and its core product, givastomig, showing promising potential. However, there are concerns about the company's ability to secure necessary regulatory approvals and the limited addressable market for its products, with only a fraction of gastric cancer patients having the specific biomarkers targeted by NovaBridge's treatments. Additionally, there may be challenges with real-world adoption of givastomig due to infusion times and complexities.

NovaBridge Biosciences (NBP) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NovaBridge Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NovaBridge Biosciences (NBP) Forecast

Analysts have given NovaBridge Biosciences (NBP) a Strong Buy based on their latest research and market trends.

According to 1 analysts, NovaBridge Biosciences (NBP) has a Strong Buy consensus rating as of Jul 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NovaBridge Biosciences (NBP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.